ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a hold rating in a research report report published on Wednesday morning.

Several other equities research analysts also recently weighed in on the company. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Piper Sandler started coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective on the stock. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $59.81 on Wednesday. The firm’s fifty day simple moving average is $56.62 and its two-hundred day simple moving average is $58.49. The firm has a market capitalization of $1.26 billion, a P/E ratio of -108.75 and a beta of 0.74. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter last year, the company posted $1.05 earnings per share. The business’s quarterly revenue was up 12.5% on a year-over-year basis. Analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,381 shares of company stock valued at $2,441,556. 12.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Pacer Advisors Inc. grew its stake in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after acquiring an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares during the last quarter. abrdn plc purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at approximately $13,155,000. Bank of Montreal Can acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at approximately $13,043,000. Finally, Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals during the third quarter worth approximately $11,670,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.